Arvinas (ARVN) Equity Average (2017 - 2026)
Arvinas (ARVN) recorded quarterly Equity Average of $410.4 million in Q1 2026, down 17.79% quarter-over-quarter from $499.2 million in Q4 2025, and down 32.83% on a YoY basis from $610.9 million in Q1 2025.
Arvinas (ARVN) Equity Average (2017 - 2026) Analysis & Trends
Arvinas' Equity Average history runs 10 years deep, the most recent figure standing at $410.4 million for Q1 2026.
- In Q1 2026, Equity Average fell 32.83% year-over-year to $410.4 million; the TTM figure through Mar 2026 stood at $410.4 million (down 32.83% YoY), while the FY2025 annual figure was $497.8 million, down 18.51% from the prior year.
- Equity Average was $410.4 million for Q1 2026 at Arvinas, down from $499.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $752.5 million in Q1 2022 to a low of $410.4 million in Q1 2026.
- Historically, Equity Average has averaged $581.3 million across 5 years, with a median of $593.1 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Equity Average climbed 28.82% in 2024, then tumbled 32.83% in 2026.
- A 5-year view of Equity Average shows it stood at $593.2 million in 2022, then dropped by 5.83% to $558.6 million in 2023, then climbed by 2.73% to $573.8 million in 2024, then decreased by 13.02% to $499.2 million in 2025, then dropped by 17.79% to $410.4 million in 2026.
- The last three Equity Average figures came in at $410.4 million (Q1 2026), $499.2 million (Q4 2025), and $586.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 410.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 410.35 Mn |
| Dec 31, 2025 | 499.15 Mn |
| Sep 30, 2025 | 586.85 Mn |
| Jun 30, 2025 | 634.70 Mn |
| Mar 31, 2025 | 610.90 Mn |
| Dec 31, 2024 | 573.85 Mn |
| Sep 30, 2024 | 593.10 Mn |
| Jun 30, 2024 | 604.95 Mn |
| Mar 31, 2024 | 634.85 Mn |
| Dec 31, 2023 | 558.60 Mn |
| Sep 30, 2023 | 460.40 Mn |
| Jun 30, 2023 | 487.30 Mn |
| Mar 31, 2023 | 537.95 Mn |
| Dec 31, 2022 | 593.20 Mn |
| Sep 30, 2022 | 646.05 Mn |
| Jun 30, 2022 | 696.95 Mn |
| Mar 31, 2022 | 752.50 Mn |
| Dec 31, 2021 | 799.70 Mn |
| Sep 30, 2021 | 700.30 Mn |
| Jun 30, 2021 | 599.05 Mn |